Citi raised the firm’s price target on Sotera Health (SHC) to $21 from $17 and keeps a Neutral rating on the shares. The firm adjusted models in the life science tools and diagnostics group ahead of the Q3 reports.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC: